Eli P Darnell1, Meghan J Mooradian2,3, Erez N Baruch4,5, Melis Yilmaz3, Kerry L Reynolds6,7. 1. Division of Internal Medicine, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA. 2. Division of Medical Oncology, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA. 3. Harvard Medical School, Boston, MA, USA. 4. Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel. 5. Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, P.O. Box 39040, 6997801, Tel Aviv, Israel. 6. Division of Medical Oncology, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA. kreynolds7@partners.org. 7. Harvard Medical School, Boston, MA, USA. kreynolds7@partners.org.
Abstract
PURPOSE OF REVIEW: While immune checkpoint inhibitor (ICI) therapy has improved melanoma patient outcomes, it has also resulted in the rise of unique immune-related adverse events (irAEs). Here, we review and synthesize irAE management recommendations from several oncological societies into a streamlined format to aid in diagnosis and management. We also include clinical pearls highlighting several recent research studies in this field. RECENT FINDINGS: Knowledge of immunotherapy toxicity has continually evolved, and several major oncologic societies have recently released new or updated guidelines. Keeping up with the evolving field of immunotherapy and related toxicities is crucial, because ICI use, in combination with other agents, will only continue to increase and likely result in new and different patterns of irAEs. Providing clear and concise references for clinicians will help ensure proper irAE evaluation and management going forward. We present one such reference here, covering management of common and/or serious irAEs.
PURPOSE OF REVIEW: While immune checkpoint inhibitor (ICI) therapy has improved melanoma patient outcomes, it has also resulted in the rise of unique immune-related adverse events (irAEs). Here, we review and synthesize irAE management recommendations from several oncological societies into a streamlined format to aid in diagnosis and management. We also include clinical pearls highlighting several recent research studies in this field. RECENT FINDINGS: Knowledge of immunotherapy toxicity has continually evolved, and several major oncologic societies have recently released new or updated guidelines. Keeping up with the evolving field of immunotherapy and related toxicities is crucial, because ICI use, in combination with other agents, will only continue to increase and likely result in new and different patterns of irAEs. Providing clear and concise references for clinicians will help ensure proper irAE evaluation and management going forward. We present one such reference here, covering management of common and/or serious irAEs.
Authors: Karthik Suresh; Kevin J Psoter; Khinh Ranh Voong; Bairavi Shankar; Patrick M Forde; David S Ettinger; Kristen A Marrone; Ronan J Kelly; Christine L Hann; Benjamin Levy; Josephine L Feliciano; Julie R Brahmer; David Feller-Kopman; Andrew D Lerner; Hans Lee; Lonny Yarmus; Russell K Hales; Franco D'Alessio; Sonye K Danoff; Jarushka Naidoo Journal: J Thorac Oncol Date: 2018-11-30 Impact factor: 15.609
Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544
Authors: Mario Sznol; Michael A Postow; Marianne J Davies; Anna C Pavlick; Elizabeth R Plimack; Montaser Shaheen; Colleen Veloski; Caroline Robert Journal: Cancer Treat Rev Date: 2017-06-22 Impact factor: 12.111
Authors: Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245
Authors: Alyce M Kuo; Lukas Kraehenbuehl; Stephanie King; Donald Y M Leung; Elena Goleva; Andrea P Moy; Mario E Lacouture; Neil J Shah; David M Faleck Journal: Cancers (Basel) Date: 2022-06-17 Impact factor: 6.575
Authors: Massimo Ralli; Andrea Botticelli; Irene Claudia Visconti; Diletta Angeletti; Marco Fiore; Paolo Marchetti; Alessandro Lambiase; Marco de Vincentiis; Antonio Greco Journal: J Immunol Res Date: 2020-06-28 Impact factor: 4.818